{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:05:19Z","timestamp":1789067119795,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T00:00:00Z","timestamp":1506729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40263-017-0467-3","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T02:38:57Z","timestamp":1506739137000},"page":"891-898","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany"],"prefix":"10.1007","volume":"31","author":[{"given":"Brendan J.","family":"Snellgrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Steinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,30]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ejps.2016.10.004","volume":"96","author":"L Fijalkowski","year":"2017","unstructured":"Fijalkowski L, Salat K, Podkowa A, Zareba P, Nowaczyk A. Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-Molecular docking and pharmacodynamic studies. Eur J Pharm Sci. 2017;96:362\u201372. doi:\n                        10.1016\/j.ejps.2016.10.004\n                        \n                    .","journal-title":"Eur J Pharm Sci"},{"key":"467_CR2","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1213\/01.ane.0000287643.13410.5e","volume":"105","author":"NM Gajraj","year":"2007","unstructured":"Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805\u201315. doi:\n                        10.1213\/01.ane.0000287643.13410.5e\n                        \n                    .","journal-title":"Anesth Analg"},{"key":"467_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-016-0390-z","volume":"30","author":"R Freynhagen","year":"2016","unstructured":"Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, et al. Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs. 2016;30:1191\u2013200. doi:\n                        10.1007\/s40263-016-0390-z\n                        \n                    .","journal-title":"CNS Drugs"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","volume":"77","author":"KE Evoy","year":"2017","unstructured":"Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403\u201326. doi:\n                        10.1007\/s40265-017-0700-x\n                        \n                    .","journal-title":"Drugs."},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","volume":"30","author":"O Schjerning","year":"2016","unstructured":"Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30:9\u201325. doi:\n                        10.1007\/s40263-015-0303-6\n                        \n                    .","journal-title":"CNS Drugs"},{"key":"467_CR6","unstructured":"IMS Health HQ Limited. Top 20 global products 2015. 2015. \n                        https:\/\/www.imshealth.com\/files\/web\/Corporate\/News\/Top-Line%20Market%20Data\/Top_20_Global_Products_2015.pdf\n                        \n                    . Accessed 15 Sept 2017."},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/ajad.12159","volume":"24","author":"T Wilens","year":"2015","unstructured":"Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24:173\u20137. doi:\n                        10.1111\/ajad.12159\n                        \n                    .","journal-title":"Am J Addict."},{"key":"467_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000355268","volume":"20","author":"CRW Baird","year":"2014","unstructured":"Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115\u20138. doi:\n                        10.1159\/000355268\n                        \n                    .","journal-title":"Eur Addict Res"},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","volume":"69","author":"M Grosshans","year":"2013","unstructured":"Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021\u20135. doi:\n                        10.1007\/s00228-013-1578-5\n                        \n                    .","journal-title":"Eur J Clin Pharmacol"},{"key":"467_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","volume":"174","author":"T Abrahamsson","year":"2017","unstructured":"Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58\u201364. doi:\n                        10.1016\/j.drugalcdep.2017.01.013\n                        \n                    .","journal-title":"Drug Alcohol Depend"},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","volume":"241","author":"M Hakkinen","year":"2014","unstructured":"Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1\u20136. doi:\n                        10.1016\/j.forsciint.2014.04.028\n                        \n                    .","journal-title":"Forensic Sci Int"},{"key":"467_CR12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2174\/1874473710801030255","volume":"1","author":"SP Barrett","year":"2008","unstructured":"Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008;1:255\u201362.","journal-title":"Curr Drug Abuse Rev."},{"key":"467_CR13","unstructured":"O\u2019brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28\u201333."},{"key":"467_CR14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0885-3924(95)00187-5","volume":"11","author":"RK Portenoy","year":"1996","unstructured":"Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manag. 1996;11:203\u201317.","journal-title":"J Pain Symptom Manag"},{"key":"467_CR15","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s00115-014-4016-8","volume":"85","author":"F Hoffmann","year":"2014","unstructured":"Hoffmann F, Glaeske G. Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012. Nervenarzt. 2014;85:1402\u20139. doi:\n                        10.1007\/s00115-014-4016-8\n                        \n                    .","journal-title":"Nervenarzt."},{"key":"467_CR16","volume-title":"Strukturiertes Klinisches Interview f\u00fcr DSM-IV, Achse I: psychische St\u00f6rungen, Interviewheft","author":"H-U Wittchen","year":"1997","unstructured":"Wittchen H-U, Wunderlich U, Gruschwitz S, Zaudig M. Strukturiertes Klinisches Interview f\u00fcr DSM-IV, Achse I: psychische St\u00f6rungen, Interviewheft. G\u00f6ttingen: Hogrefe; 1997."},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.4088\/JCP.15l10296","volume":"77","author":"J Mutschler","year":"2016","unstructured":"Mutschler J, Gastberger S, Baumgartner MR, Grosshans M, Seifritz E, Quednow BB, Herdener M. Pregabalin use among opioid-addicted patients in Switzerland. J Clin Psychiatry. 2016;77:1202\u20133. doi:\n                        10.4088\/JCP.15l10296\n                        \n                    .","journal-title":"J Clin Psychiatry"},{"key":"467_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13011-016-0062-5","volume":"11","author":"H Alblooshi","year":"2016","unstructured":"Alblooshi H, Hulse GK, El Kashef A, Al Hashmi H, Shawky M, Al Ghaferi H, et al. The pattern of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation Centre cohort study. Subst Abuse Treat Prev Policy. 2016;11:19. doi:\n                        10.1186\/s13011-016-0062-5\n                        \n                    .","journal-title":"Subst Abuse Treat Prev Policy."},{"key":"467_CR19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","volume":"69","author":"M Gahr","year":"2013","unstructured":"Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335\u201342. doi:\n                        10.1007\/s00228-012-1464-6\n                        \n                    .","journal-title":"Eur J Clin Pharmacol"},{"key":"467_CR20","first-page":"227","volume":"13","author":"H-U Wittchen","year":"2011","unstructured":"Wittchen H-U, B\u00fchringer G, Rehm JT, Soyka M, Tr\u00e4der A, Trautmann S. The Social, clinical and treatment situation of opioid maintenance treatment in a prevalence sample of patients at baseline. Suchtmed. 2011;13:227\u201331.","journal-title":"Suchtmed."},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000321079","volume":"80","author":"F Schifano","year":"2011","unstructured":"Schifano F, D\u2019Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118\u201322. doi:\n                        10.1159\/000321079\n                        \n                    .","journal-title":"Psychother Psychosom"},{"key":"467_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejphar.2014.08.030","volume":"742","author":"P Hasanein","year":"2014","unstructured":"Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol. 2014;742:113\u20137. doi:\n                        10.1016\/j.ejphar.2014.08.030\n                        \n                    .","journal-title":"Eur J Pharmacol"},{"key":"467_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12538","author":"E Vashchinkina","year":"2017","unstructured":"Vashchinkina E, Piippo O, Vekovischeva O, Krupitsky E, Ilyuk R, Neznanov N, et al. Addiction-related interactions of pregabalin with morphine in mice and humans: reinforcing and inhibiting effects. Addict Biol. 2017. doi:\n                        10.1111\/adb.12538\n                        \n                    .","journal-title":"Addict Biol"},{"key":"467_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-0032-1305042","volume":"39","author":"N Kammerer","year":"2012","unstructured":"Kammerer N, Lemenager T, Grosshans M, Kiefer F, Hermann D. Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax. 2012;39:351\u20132. doi:\n                        10.1055\/s-0032-1305042\n                        \n                    .","journal-title":"Psychiatr Prax"},{"key":"467_CR25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bcp.12277","volume":"78","author":"V Kapil","year":"2014","unstructured":"Kapil V, Green JL, Le Lait M-C, Wood DM, Dargan PI. Misuse of the gamma-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190\u20131.","journal-title":"Br J Clin Pharmacol"},{"key":"467_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","volume":"28","author":"F Schifano","year":"2014","unstructured":"Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491\u20136. doi:\n                        10.1007\/s40263-014-0164-4\n                        \n                    .","journal-title":"CNS Drugs"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0467-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T12:36:02Z","timestamp":1509021362000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,30]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0467-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,30]]}}}